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Drosophila S2 insect cell expression is less known than the extensively used Spodoptera or Trichoplusia ni (Hi-
5) insect cell based Baculovirus expression system (BEVS). Nevertheless it has been used in research for 
almost 40 years. The cell line was derived from late stage Drosophila melanogaster (Fruit fly) embryos by 
Schneider in the 1970s, who named the cell line Drosophila Schneider line 2 (synonyms: S2, SL2, D.mel. 2). 
The system has been widely applied to fundamental research, where the availability of the whole genome 
sequence of Drosophila melanogaster (1, 2) and the S2 cells’ susceptibility to RNA interference methods (3, 4) 
have enabled genome wide RNAi screening and whole genome expression analysis techniques to be used to 
great effect. S2 cells have proved to be highly effective for the production of proteins from a great variety of 
protein classes (5), such as: viral proteins, toxins, membrane proteins, enzyme, etc. Recent publications have 
also shown the strength of the S2 system in expression of Virus Like Particles (VLPs) (6). 
ExpreS2ion has developed the ExpreS2, Drosophila S2 platform to achieve improved yields for difficult to 
express proteins. Furthermore, several technologies have been developed to improve the ease of use of the 
system, as well as enable fast and efficient screening of multiple constructs.  
S2 based production processes for two malaria vaccine clinical trails with The Jenner Institute, Oxford University 
(Rh5 (7,8), blood-stage malaria) and Copenhagen University (VAR2CSA (9) pregnancy associated malaria) 
have been developed. The placental malaria vaccine is currently in a phase Ia trail in Germany, and a Phase Ib 
trial in Benin. The blood-stage malaria vaccine is currently in Phase IIa trial and is expecting results by the end 
of 2018.  
 
Several transmission-blocking candidates have been identified over the years with some of the most prominent 
being pfs48/45, Pfs230C and Pfs25(10). Other vaccine targets focus on blood-stage malaria such as Rh5, 
PfRIPR and CyrPA. We will present data on the development of a high producing Pfs25 monoclonal cell line and 
the purification from said cell line,as well as expression data on a range of other malaria vaccine targets. 
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